ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / NTHI / insiders
NRXP (25) ORGO (34) PMVP (42) VTVT (24) ⌘ Pro Terminal β†’

NeOnc Technologies Holdings Inc. (NTHI) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.07 -5.83% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.03

NeOnc Technologies Holdings Inc. (NTHI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $97.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NTHI Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is NTHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.07 (-5.83% 1D, market cap $97.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NTHI ranks #765 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does NTHI compare to NRXP and ORGO in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NTHI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, NRXP (NRX Pharmaceuticals Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M) and ORGO (Organogenesis Holdings Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $98.8M). Among the 5-stock peer group, NTHI leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NTHI?
β–Ό

Per NTHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001979414), NeOnc Technologies Holdings Inc. generated $40.0K in revenue (-51.8% YoY), -$62.1M in net income, and -$20.4M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.03 (-1.24%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (31/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (7)Whales (7)SEC (7)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
$13 Bull$3 Base$2 Bear
πŸ“¬ FREE NTHI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for NTHI)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
πŸ” WHY NTHI SCORES 31/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–² #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
23
Grade E$2.60+6.5% Next Q
Q2 (-2Q)
26
Grade E$2.77+8.3% Next Q
Q3 (-1Q)
28
Grade E$3.00+2.3% Next Q
Current
31
Grade E$3.07-9.4% Hist 90D Ξ±
Trajectory: E (23) β†’ E (31)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a NTHI Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While NTHI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.42) and Max Pain ($3.22) forces dealer call-delta covering toward $12.60.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NTHIβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œNTHI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

NTHI Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NTHI)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NTHI. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NTHI)

  • βœ“Walkthrough of NTHI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
NTHI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.85%β–Ό DESCENDING CHANNEL
2026-11-03O $3.12H $3.26L $3.07C $3.07VOL 131.7K
RES: $5.03SUP: $2.36SMA50: $3.42SMA200: $5.41
$8.65$6.98$5.32$3.65$1.98RES $5.03SUP $2.36$3.072026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NTHI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ NTHI Butterfly Map β†’ + Track NTHI β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -51.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NTHI today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for NTHI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NTHI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NTHI)

Health Care Rank #765 of 1015 βš”οΈ NRXP vs NTHI Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (NTHI vs. NRXP, ORGO, PMVP, VTVT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NeOnc Technologies Holdings Inc. (NTHI) ranks #765 by composite RQD confidence (31/100, grade E) and #657 by equity capitalization ($97.0M). Within this direct 5-issuer industry benchmark cohort, NTHI leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and β€” gross margin. PMVP currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with NTHI at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NTHI ACTIVE
NeOnc Technologies Holdings Inc.
E 31/100 β€” β€” -35.0% -5.83% $97.0M Benchmark Subject
NRXP
NRX Pharmaceuticals Inc.
E 25/100 β€” 58.8% -35.0% -4.40% $98.3M /nrxp-vs-nthi β†’
ORGO
Organogenesis Holdings Inc. (Class A)
E 34/100 β€” β€” 17.1% -1.64% $98.8M /orgo-vs-nthi β†’
PMVP
PMV Pharmaceuticals Inc.
D- 42/100 β€” β€” -35.0% +4.58% $98.9M /pmvp-vs-nthi β†’
VTVT
vTv Therapeutics Inc. (Class A)
E 24/100 β€” β€” -35.0% -4.05% $99.5M /vtvt-vs-nthi β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001979414 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NeOnc Technologies Holdings Inc. (NTHI) reported GAAP revenue of $40.0K (-51.8% vs. FY2024 revenue of $83.0K ) , GAAP net income of -$62.1M, operating cash flow of -$20.4M, and free cash flow of -$20.4M (-383.3% YoY). On the balance sheet, NTHI closed FY2025 with $2.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $40.0K -$62.1M -$20.4M -$20.4M $2.8M β€”
FY2024 (FY) 2024-12-31 $83.0K -$11.9M -$4.2M -$4.2M $3.4M β€”

3. NTHI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NTHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.07 (-5.83% 1D, market cap $97.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NTHI ranks #765 in composite RQD confidence.

How does NTHI compare to NRXP and ORGO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NTHI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, NRXP (NRX Pharmaceuticals Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M) and ORGO (Organogenesis Holdings Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $98.8M). Among the 5-stock peer group, NTHI leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NTHI?

Per NTHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001979414), NeOnc Technologies Holdings Inc. generated $40.0K in revenue (-51.8% YoY), -$62.1M in net income, and -$20.4M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NTHI trading relative to its 50-day, 200-day, and 52-week technical levels?

NTHI last traded at $3.07 (-5.83% on volume of 93,905 shares), positioning the stock -10.23% below its 50-day simple moving average ($3.42) and -43.25% below its 200-day simple moving average ($5.41). Across its 52-week range of $2.50 to $12.00, NTHI sits at the 6.0% percentile with a 14-day RSI of 54.3 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($2.69 to $3.45).

Direct Sub-Reports: NTHI RQD Cockpit NTHI 12M Forecast NTHI Earnings & Move NTHI Dividends & DRIP NTHI Insiders & 13F NTHI Whale Options NTHI Profit Sankey NTHI News & Why
ROARABLE RATING BRIEF β€’ RQD 31/100 (E) βœ“ SEC XBRL & RQD VERIFIED

NTHI β€” NeOnc Technologies Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NeOnc Technologies Holdings Inc. (NTHI) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.07 (-5.83% 1D, market capitalization $97.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of -21.93%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NeOnc Technologies Holdings Inc. (NTHI) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..1B. Revenue, customer base, and product details are β€” The reported revenue of β€” for FY 2025 and $0.1M for FY 2024 indicates minimal top-line activity .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NeOnc Technologies Holdings Inc. (NTHI) reported $40.0K in annual revenue (up from $83.0K in FY2024, -51.8% YoY) and -$62.1M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($83.0K revenue, -$11.9M net income) through FY2025, NTHI scaled operating cash flow to -$20.4M and free cash flow to -$20.4M, backed by $2.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -21.93% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $2.50 – $12.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded.

  • Key Question #1: Can NTHI sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $40.0K and free cash flow of -$20.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NTHI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NTHI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NeOnc Technologies Holdings Inc. (NTHI) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to NTHI Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NTHI Bull vs. Bear Conversation Board β€” What's Your Call at $3.07?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NTHI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NTHI:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER β€’ Institutional Buy-Side πŸ‚ BULLISH 🎯 Target: $4.07 (+24.8%)
πŸ“Œ Pinned Debate

Shares trade near the lower-middle of their 52-week range with a Beta of 1.0 and a 2.97% gain on the day, while the company has disclos

Don't sleep on NTHI's setup in Health Care. Shares trade near the lower-middle of their 52-week range with a Beta of 1.0 and a 2.97% gain on the day, while the company has disclosed clinical data readouts including a 48.9% six-month progression-free rate.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.

ArenaChamp_24 πŸ‚ BULL

@DeepValue_CFA Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.26 and keeping dry powder in case we test $3.03.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.74 (-16.0%)
Spot @ $3.26

Operating losses widened to -$58.2M in FY 2025 with ROIC at -35%, FCF yield at -21.93%, cash of only $0.1M, and an Insider Conviction p

Here is the bear case nobody on the bull side wants to address on NTHI: Operating losses widened to -$58.2M in FY 2025 with ROIC at -35%, FCF yield at -21.93%, cash of only $0.1M, and an Insider Conviction pillar score of 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE